ArticleScientific reports2024

Inhibition of LATS kinases reduces tumorigenicity and increases the sensitivity of human chronic myelogenous leukemia cells to imatinib.

Phatchanat Klaihmon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.